Stockreport

NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC [Yahoo! Finance]

NeuroSense Therapeutics Ltd.  (NRSN) 
PDF PrimeC has already demonstrated a significant impact on slowing disease progression and increasing survival rates in people living with ALS CAMBRIDGE, Mass. Dec. 11, [Read more]